Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 89

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 89
---
. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such securities litigation, it could result in substantial costs and a diversion of management’s
resources and attention, which could harm our business. Future sales of our common stock could also reduce the market price of our stock.

58

Moreover,
the liquidity of our common stock will be limited, not only in terms of the number of shares of common stock that can be bought and sold
at a given price, but by potential delays in the timing of executing transactions in our common stock and a reduction in security analyst
and media’s coverage of us, if any. These factors may result in lower prices for our common stock than might otherwise be obtained
and could also result in a larger spread between the bid and ask prices for our common stock. In addition, without a large float, our
common stock will be less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our
common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate their investment
in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our common
stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the
future.

An
active trading market for our common stock may not be sustained.

An
active public trading market for our common stock may not be sustained. The lack of an active market may impair your ability to sell
your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce
the fair value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling
shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.

If
securities or industry analysts do not publish or cease publishing research or reports, or publish unfavorable reports about us, our
business or our market, our share price and trading volume could be negatively impacted.

The
trading market for our common stock could be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts and cannot provide any assurance
that analysts will